Free Trial
ASX:EX1

Exopharm (EX1) Stock Price, News & Analysis

About Exopharm Stock (ASX:EX1)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
A$1.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive EX1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exopharm and its competitors with MarketBeat's FREE daily newsletter.

EX1 Stock News Headlines

Tryptamine Therapeutics Ltd (TYP)
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
EX1 - Weather warnings issued
Exopharm Limited (EX1.XA)
See More Headlines

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:EX1
CIK
N/A
Fax
N/A
Employees
50
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-A$4.32 million
Net Margins
-1,756.70%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
A$1.18 million
Price / Cash Flow
3.39
Book Value
A$0.02 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
A$1.93 million
Optionable
Not Optionable
Beta
1.26
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (ASX:EX1) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners